

Psychedelic APIs


Psychedelics are emerging as promising therapies in the treatment of various neurological and psychiatric conditions. Though psychedelics are controlled substances in most countries, clinical trials exploring the use of psychedelics are underway. Psychedelics have potential in the treatment of numerous conditions, including major depressive disorder, anxiety, post-traumatic stress disorder (PTSD), substance use disorder, cluster headaches, as well as psychological distress associated with end of life.

- US FDA and EMA compliant
- Analytical standards of impurities and degradation products available
- DEA licensed facility for manufacturing, analysis, and export



Commercial API Production

CGMP Psilocybin




CAS Number 520-52-5

DEA Schedule I

Drug Code 7437

Availability GMP material suitable for Phase 1 and Phase 2 trials is available.

CGMP Psilocin



CAS Number 520-53-6


DEA Schedule I

Drug Code 7438

Availability GMP material suitable for Phase 1 and Phase 2 trials is available.


Psychedelic APIs in Development

3,4-MDMA



CAS Number 42542-10-9
DEA Schedule I
Drug Code 7405

N,N-DMT



CAS Number 61-50-7
DEA Schedule I
Drug Code 7435